Synthetic CBD derivative prevents seizures in mice without causing sedation

Researchers at the University of Nevada Las Vegas have developed a synthetic CBD derivative that reduces seizure severity in mice without causing sedation. This compound, which features an elongated chemical tail, was found to protect against chemically induced seizures while maintaining normal brain cell development. Developmental epilepsy syndromes, a rare genetic disorder, often involve a lack of inhibitory control over brain cell activity and can lead to cognitive deficits.

Traditional anti-seizure medications, such as benzodiazepines, can cause physical dependence and adverse side effects in children. CBD, derived from the cannabis plant, has shown promise as a non-psychoactive alternative to these medications. The synthetic CBD derivative, named (+)-CBD-oct, was tested in a series of studies to evaluate its efficacy and safety as an anti-seizure medication.

The researchers found that (+)-CBD-oct increased electrical power in the delta and theta frequency bands, associated with deep relaxation and memory processing. Importantly, the compound did not cause sedation or reduce exploration in mice, distinguishing it from traditional benzodiazepines. When tested for its ability to stop seizures, (+)-CBD-oct showed significant promise.

Mice pre-treated with the synthetic compound experienced fewer and less intense seizures compared to those given placebo or natural CBD. In a genetically modified mouse model of developmental epilepsy, (+)-CBD-oct reduced seizure severity, delayed seizure onset, lowered seizure frequency, and improved survival rates. The researchers also investigated the compound's effects on the developing brain, finding that (+)-CBD-oct did not alter dendritic spines in normal mouse pups or mutant epilepsy mouse pups.

These findings suggest that the synthetic CBD derivative (+)-CBD-oct may be a safer and more effective alternative to traditional anti-seizure medications for treating developmental epilepsy in children.